文献速递胸部肿瘤

SMARCA4缺陷胸部肉瘤样肿瘤主要为吸烟相关未分化癌而非原发肉瘤

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
PubMed 文献 · J Thorac Oncol · 2019-11-18

该研究对比22例SMARCA4缺陷胸部肉瘤样肿瘤(SD-TST)与45例SMARCA4缺陷非小细胞肺癌(SD-NSCC),通过组织学、免疫组化及341-468基因测序分析,发现SD-TST具有NSCC成分或标志物表达、吸烟史及吸烟基因组特征,提示其本质为吸烟相关未分化/去分化癌而非原发肉瘤。

要点

  • SD-TST应视为吸烟相关未分化癌,而非原发胸部肉瘤。
  • 与SD-NSCC相比,SD-TST原发瘤更大、生存更差、更常见于30-50岁。
  • SD-TST特征包括claudin-4缺失、SMARCA2共缺陷及干细胞标志物表达。

核心结论

  • SD-TST主要为吸烟相关未分化/去分化癌,而非原发胸部肉瘤,尽管与NSCC有组织发生关系,但具有独特临床病理特征,应视为独立实体。

研究设计与样本

  • 研究纳入22例具有圆形细胞和/或横纹肌样形态的SD-TST和45例SD-NSCC,进行临床病理、免疫组化及基因组分析,使用341-468基因二代测序及其他分子平台。

主要发现

  • 5例SD-TST中可见NSCC成分与肉瘤样区域毗邻,另4例局灶表达NSCC谱系标志物TTF1或p40。
  • 除1例外所有SD-TST患者均有吸烟史(平均51包年),并伴有基因组吸烟特征。
  • 部分SD-TST具有高肿瘤突变负荷(平均14.2个突变/兆碱基)及NSCC特征性突变。
  • 与SD-NSCC相比,SD-TST原发肿瘤显著更大(p < 0.0001)、生存更差(p = 0.004),更常见于较年轻年龄(30-50岁)尽管吸烟史更重。
  • SD-TST一致缺乏黏附分子claudin-4,存在SMARCA2(BRM)共缺陷,并频繁表达干细胞标志物。

临床怎么用

  • 对于SMARCA4缺陷的胸部肉瘤样肿瘤,应认识到其可能为吸烟相关未分化癌,需结合吸烟史、NSCC标志物及分子特征进行鉴别诊断。

局限性

  • 样本量有限(22例SD-TST和45例SD-NSCC),需进一步研究确定该罕见侵袭性肿瘤的治疗方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Highly aggressive thoracic neoplasms characterized by SMARCA4 (BRG1) deficiency and undifferentiated round cell or rhabdoid morphology have been recently described and proposed to represent thoracic sarcomas. However, it remains unclear whether such tumors may instead represent sarcomatoid carcinomas, and how their clinicopathologic characteristics compare with those of nonsarcomatoid SMARCA4-deficient non-small cell lung carcinomas (SD-NSCC). METHODS: We identified 22 SMARCA4-deficient thoracic sarcomatoid tumors (SD-TSTs) with round cell and/or rhabdoid morphology and 45 SD-NSCCs, and comprehensively analyzed their clinicopathologic, immunohistochemical, and genomic characteristics using 341-468 gene next-generation sequencing and other molecular platforms. RESULTS: The relationship of SD-TSTs with NSCC was supported by (1) the presence of NSCC components juxtaposed with sarcomatoid areas in five cases, (2) focal expression of NSCC lineage markers TTF1 or p40 in four additional cases, (3) smoking history in all except one patient (mean = 51 pack-years), accompanied by genomic smoking signature, and (4) high tumor mutation burden (mean = 14.2 mutations per megabase) and mutations characteristic of NSCC in a subset. Compared with SD-NSCCs, SD-TSTs exhibited considerably larger primary tumor size (p < 0.0001), worse survival (p = 0.004), and more frequent presentation at younger age (30-50 years) despite heavier smoking history. Distinctive pathologic features of SD-TSTs included consistent lack of adhesion molecule claudin-4, SMARCA2 (BRM) codeficiency, and frequent expression of stem cell markers. CONCLUSIONS: SD-TSTs represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. Despite their histogenetic relationship with NSCC, these tumors have unique clinicopathologic characteristics, supporting their recognition as a distinct entity. Further studies are warranted to determine therapeutic approaches to this novel class of exceptionally aggressive thoracic tumors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. J Thorac Oncol. 2019. PMID: 31751681. doi:10.1016/j.jtho.2019.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。